ArticleDiscover oncology2026
Pro-tumorigenic role of protocadherin 17 and its prognostic significance in Ewing sarcoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ewing sarcoma (ES) is an aggressive bone tumor in children and adolescents, and metastatic dissemination remains the major cause of treatment failure. Protocadherin 17 (PCDH17), a member of the cadherin superfamily, has been reported to exert context-dependent roles in solid tumors, but its significance in ES is unclear. Here, we analyzed Gene Expression Omnibus (GEO) datasets to evaluate PCDH17 expression, its association with overall survival and event-free survival, and the enrichment of biological pathways related to PCDH17 levels, and further examined PCDH17 expression in ES cell lines. The biological functions of PCDH17 were investigated using short hairpin RNA-mediated knockdown in A673 and RD-ES cells, followed by Cell counting kit-8 (CCK-8), colony formation, wound healing and transwell invasion assay, as well as western blotting (WB) and immunofluorescence (IF). PCDH17 was markedly upregulated in ES tissues and cell lines compared with normal counterparts, and high expression correlated with shorter survival. Gene set enrichment analysis (GSEA) indicated that high PCDH17 expression is associated with transcriptional programs driving cell cycle progression and oncogenic growth. Functionally, silencing PCDH17 significantly impairs proliferation, colony formation, migration and invasion of ES cells, and attenuates mesenchymal marker expression as well as associated morphological features. Collectively, our data indicate that PCDH17 is upregulated in ES and associated with worse survival, and that PCDH17 depletion suppresses malignant phenotypes in vitro. Together, these results nominate PCDH17 as a candidate prognostic biomarker and potential therapeutic target, which merits further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.